1036389-83-9|2-Bromo-4-fluoro-5-nitrobenzoic acid| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 1036389-83-9 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 1036389-83-9 ]

CAS No. :	1036389-83-9
Formula :	C₇H₃BrFNO₄
M.W :	264.01
SMILES Code :	O=C(O)C1=CC([N+]([O-])=O)=C(F)C=C1Br
MDL No. :	MFCD11847619
InChI Key :	APETYHSLTIVOQX-UHFFFAOYSA-N
Pubchem ID :	19826518

Safety of [ 1036389-83-9 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 1036389-83-9 ] Show Less

Physicochemical Properties

Num. heavy atoms	14
Num. arom. heavy atoms	6
Fraction Csp3	0.0
Num. rotatable bonds	2
Num. H-bond acceptors	5.0
Num. H-bond donors	1.0
Molar Refractivity	49.88
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	83.12 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.75
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	2.07
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.61
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.69
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	0.24
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.47

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.97
Solubility	0.285 mg/ml ; 0.00108 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.44
Solubility	0.0948 mg/ml ; 0.000359 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.29
Solubility	1.37 mg/ml ; 0.00519 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.44 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.56

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	2.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<0.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.97

Application In Synthesis of [ 1036389-83-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1036389-83-9 ]

[ 1036389-83-9 ] Synthesis Path-Downstream 1~29

1
[ 67-56-1 ]
[ 1036389-83-9 ]
2-bromo-4-fluoro-5-nitrobenzoic acid methyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
99%	With thionyl chloride; at 60℃; for 18h;	Under ice-cooling, thionyl chloride (4.1 mL, 56.0 mmol) was added dropwise to dry methanol (244 ml of), and after completion of dropwise addition, stirring was continued for 30 minutes under these conditions.2-Bromo-4-fluoro-benzoic acid (13.4g, 50.8mmoL), the reaction was heated at 60 deg.] C for 18 hours.The solvent was distilled off under reduced pressure, ethyl acetate was added, washed with saturated sodium carbonate, the solvent was distilled off under reduced pressure, dried under high vacuum to give a pale yellow solid 14g, yield 99%.
90%		(7.09 ml, 97.62 mmol) was added dropwise to anhydrous methanol (150 ml) under ice-cooling, and the mixture was stirred for 10 minutes. 2-Bromo-4-fluoro-5-nitrobenzoic acid (10.40 g , 39.39 mmol) and transferred to an oil bath (70 & lt; 0 & gt; C) overnight.The organic phase was collected, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give a white powder. The residue was purified by silica gel column chromatography, and the filtrate was concentrated under reduced pressure. Solid 9.90 g, yield 90%.
87%		Thionyl chloride (1.673 mL, 22.92 mmol) was added to methanol (100 mL) at 0 0C and stirred for 30 min. 21A (5.5 g, 20.83 mmol) was added and the mixture was heated at 60 0C for 18 h. The reaction mixture was concentrated to a white solid and purified by column chromatography (0 to 50% EtOAc in hexanes, 120 g column) to yield 21B (5.03 g, 18.09 mmol, 87 % yield) as a white solid. MS (ESI) m/z 279.0/281.0 (M+H)+. 1H NMR (400 MHz, CDCl3) delta ppm 3.97 (s, 3 H) 7.67 (d, J=9.89 Hz, 1 H) 8.62 (d, J=7.70 Hz, 1 H).

87%	With thionyl chloride; at 0 - 60℃; for 18.5h;	Intermediate 7B:; [00207] Thionyl chloride (1.673 mL, 22.92 mmol) was added to methanol (100 mL) at 0 0C and stirred for 30 min. Intermediate 7A (5.5 g, 20.83 mmol) was added and the mixture was heated at 60 0C for 18 h. The reaction mixture was concentrated to a white solid and purified by column chromatography (0 to 50% EtOAc in hexanes, 120 g column) to yield Intermediate 7B (5.03 g, 18.09 mmol, 87 % yield) as a white solid. MS (ESI) m/z 279.0/281.0 (M+H)+.
70%	With thionyl chloride; at 0 - 120℃; for 4h;	To a solution of 184 (5.5 g, 20,9 mmol) in MeOH (50 mL) is added thionyl chloride (5 g, 42 mmol) dropwise at 0 C. After stirring at 120 C for 4 hours, the mixture is concentrated and purified by silica gel column chromatography (EA:PE = 1 :4) to give 185 as a white solid (4.0 g, 70% yield). (MS: [M+H]+ 279.1 )
29%	With sulfuric acid; at 75℃;	A mixture of 16A (11.5 g, 43.7 mmol) in methanol (230 mL) and H2SO4 (1.7 mL) was heated to 75 C. overnight. The reaction mixture was taken up in ethyl acetate and washed with saturated sodium bicarbonate. The organic fraction was dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (1/30 to 1/5 EtOAc in pet. ether) to give the compound 16B (3.5 g, 29% yield) as a white solid: 1H NMR (400 MHz, CDCl3) delta 8.63 (d, J=7.6 Hz, 1H), 7.67 (d, J=10 Hz, 1H), 3.98 (s, 3H).

References: [1]Patent: CN103804358,2016,B .Location in patent: Paragraph 0184.
[2]Patent: CN106146474,2016,A .Location in patent: Paragraph 0100 - 0102.
[3]Patent: WO2008/79759,2008,A1 .Location in patent: Page/Page column 137.
[4]Patent: WO2008/79836,2008,A2 .Location in patent: Page/Page column 92.
[5]ACS Medicinal Chemistry Letters,2016,vol. 7,p. 1077 - 1081.
[6]Patent: WO2017/176812,2017,A1 .Location in patent: Paragraph 0452.
[7]Patent: US2018/291002,2018,A1 .Location in patent: Paragraph 0444; 0446.

2
[ 1006-41-3 ]
2-bromo-4-fluoro-6-nitrobenzoic acid [ No CAS ]
[ 1036389-83-9 ]

Yield	Reaction Conditions	Operation in experiment
	With sulfuric acid; potassium nitrate; at 0 - 20℃; for 3.16667h;	Potassium nitrate (11.54 g, 114 mmol) was added portionwise to a solution of 2-bromo-4-fluorobenzoic acid (25 g, 114 mmol) in sulfuric Acid (228 mL) <n="138"/>at 0 0C over 10 min. The reaction mixture was stirred for 3 h at ambient temperature. The reaction mixture was poured onto ice. The resulting precipitate was washed with water and dried in vacuo to yield a mixture of 21A and 2-Br-4-F-6-nitrobenzoic acid (9: 1) as a white solid (19.5 g). 7 g of this solid was purified by prep HPLC (0.1% TFA, H2OMeOH, 35% to 60%) to yield 21A (5.6 g, 21.21 mmol) as a white solid. MS (ESI) m/z 262.1/264.1 (M-H)". 1H NMR (400 MHz, CD3OD) delta ppm 7.91 (d, J=10.44 Hz, 1 H) 8.61 (d, J=8.25 Hz, 1 H).;

References: [1]Patent: WO2008/79759,2008,A1 .Location in patent: Page/Page column 136-137.
[2]ACS Medicinal Chemistry Letters,2016,vol. 7,p. 1077 - 1081.

3
[ 1006-41-3 ]
[ 1036389-83-9 ]

Yield	Reaction Conditions	Operation in experiment
86%	With sulfuric acid; nitric acid; In water; at 20℃; for 1h;Cooling with ice;	Fuming nitric acid (4 ml, 45.60 mmol) was added dropwise to a mixed solution of 2-bromo-4-fluorobenzoic acid (10 g, 45.66 mmol) and concentrated sulfuric acid (34 ml) under ice-cooling.The reaction system was dripped into ice water and stirred rapidly for 1 hour. The solid was collected by filtration, washed with ice water and dried to give 10.40 g of a white solid (10.4 g), which was washed with water and evaporated to dryness to give a white solid Solid, yield 86%.
73%	With sulfuric acid; nitric acid; at 0 - 20℃; for 3h;	Fuming 113 nitric acid (8 mL) was added dropwise to a mixture of 114 2-bromo-4-fluorobenzoic acid (20 g, 91.2 mmol) in 115 concentrated sulfuric acid (68 mL) at 0 C. After stirring at room temperature for 3 h, the mixture was poured into ice water and stirred rapidly for 1 hour. The solid was collected by filtration, washed with water and dried to give 116 compound 16A (17.59 g, 73% yield) as a white solid: 1H NMR (400 MHz, CDCl3) delta 8.81 (d, J=8 Hz, 1H), 7.73 (d, J=10 Hz, 1H).
52%	With sulfuric acid; potassium nitrate; at 0 - 20℃; for 3h;	To a solution of 183 (25 g, 114 mmol) in sulfuric acid (228 mL) is added potassium nitrate (11.5 g, 114 mmol) at 0 C over 10 minutes. After stirring at room temperature for 3 hours, the mixture is poured onto ice and the solid is collected by filtration, washed with water, dned,and purified by prep-HPLC (water/MeOH with 0.1% TFA, 35% to 60%) to give 184 as a white solid (5.6 g, 52% yield). (MS: [M+Hf 265.2)

	With sulfuric acid; potassium nitrate; at 0 - 20℃; for 3.16667h;	Intermediate 7: 6-amino-5-fluoroisoindolin-l-one; <n="94"/>Intermediate 7A:; [00206] Potassium nitrate (11.54 g, 114 mmol) was added portionwise to a solution of 2-bromo-4-fluorobenzoic acid (25 g, 114 mmol) in sulfuric acid (228 mL) at 0 0C over 10 min. The reaction mixture was stirred for 3 h at ambient temperature. The reaction mixture was poured onto ice. The resulting precipitate was washed with water and dried in vacuo to yield a mixture of Intermediate 7 A and 2-Br-4-F-6- nitrobenzoic acid (9: 1) as a white solid (19.5 g). 7 g of this solid was purified by prep HPLC (0.1% TFA, H2OMeOH, 35% to 60%) to yield Intermediate 7A (5.6 g, 21.21 mmol) as a white solid. MS (ESI) m/z 262.1/264.1 (M-H)".
	With sulfuric acid; potassium nitrate; at 0 - 20℃; for 3h;	To a cooled solution of 2-bromo-4-fluorobenzoic acid (5.00 g, 22.83 mmol) in sulfuric acid (42.5 mL) at 0 C. was added potassium nitrate portionwise (2.31 g, 22.83 mmol) over 5 minutes with the resulting solution stirred at ambient temperature for 3 h. After this time the reaction mixture was poured onto ice and the resultant precipitate was filtered, washing with water and dried in vacuo for 60 h to afford a mixture of regioisomers favouring the title compound (4:1; 5.03 g, 70% yield) as an off-white solid. 1H NMR (250 MHz, DMSO-d6) delta [ppm] 8.51 (d, J=8.0 Hz, 1H), 8.17 (d, J=10.9 Hz, 1H). LCMS (Analytical Method A): Rt=0.91 min; MS (ESIPos) m/z=261.8/263.8 (M-H)-, Br isotope pattern.

References: [1]Patent: CN106146474,2016,A .Location in patent: Paragraph 0097 - 0098.
[2]Patent: US2018/291002,2018,A1 .Location in patent: Paragraph 0444; 0445.
[3]Patent: WO2017/176812,2017,A1 .Location in patent: Paragraph 0451.
[4]Patent: WO2008/79836,2008,A2 .Location in patent: Page/Page column 86-87.
[5]Patent: US2019/177279,2019,A1 .Location in patent: Paragraph 0861-0864.

Yield	Reaction Conditions	Operation in experiment
91%	With sulfuric acid; nitric acid; In water; at 20℃; for 2h;	General procedure: Under ice bath fuming nitric acid (1.0mL, 11.4mmoL) was added dropwise 2-bromo-6-fluoro-benzoic acid (2.5g, 11.4mmoL) and concentrated sulfuric acid (7.5mL) of the mixed solution.After the dropwise addition, this was stirred for 2 hours at room temperature into the system.Poured into ice water (40.0mL), a large number of solid, filtered and the solid washed with water and dried under high vacuum to give a white solid 2.5g, 83% yield.It was used directly in the next step.

5
[ 1036389-83-9 ]
[ 1036389-86-2 ]

References: [1]Patent: CN103804358,2016,B .
[2]ACS Medicinal Chemistry Letters,2016,vol. 7,p. 1077 - 1081.
[3]Patent: CN106146474,2016,A .
[4]Patent: US2018/291002,2018,A1 .

6
[ 1036389-83-9 ]
[ 1036389-88-4 ]

References: [1]ACS Medicinal Chemistry Letters,2016,vol. 7,p. 1077 - 1081.
[2]Patent: CN106146474,2016,A .
[3]Patent: US2018/291002,2018,A1 .

7
[ 1036389-83-9 ]
[ 1036389-90-8 ]

References: [1]ACS Medicinal Chemistry Letters,2016,vol. 7,p. 1077 - 1081.
[2]Patent: CN106146474,2016,A .
[3]Patent: US2018/291002,2018,A1 .

8
[ 1036389-83-9 ]
methyl 3-(1-(2-(3,4-dimethoxyphenyl)-2-(6-fluoro-3-oxoisoindolin-5-ylamino)acetyl)pyrrolidin-2-yl)-4-(isopropylsulfonyl)phenylcarbamate [ No CAS ]

References: [1]ACS Medicinal Chemistry Letters,2016,vol. 7,p. 1077 - 1081.

9
[ 1036389-83-9 ]
[ 1036389-92-0 ]

References: [1]ACS Medicinal Chemistry Letters,2016,vol. 7,p. 1077 - 1081.

10
[ 1036389-83-9 ]
2-(6-fluoro-3-oxo-isoindoline-5-yl)amino-2-methylpropionitrile [ No CAS ]

References: [1]Patent: CN106146474,2016,A .

11
[ 1036389-83-9 ]
4-[3-(6-fluoro-3-oxo-isoindoline-5-yl)-4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile [ No CAS ]

References: [1]Patent: CN106146474,2016,A .

12
[ 1036389-83-9 ]
4-{3-[6-fluoro-3-oxo-2-(pyrimidin-2-yl)-2,3-dihydro-1H-isoindol-5-yl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl}-2-(trifluoromethyl)benzonitrile [ No CAS ]

References: [1]Patent: CN106146474,2016,A .

13
[ 1036389-83-9 ]
C₁₂H₁₅BrN₂O₄ [ No CAS ]

References: [1]Patent: WO2017/176812,2017,A1 .

14
[ 1036389-83-9 ]
[ 16503-58-5 ]

References: [1]Patent: WO2017/176812,2017,A1 .

15
[ 1036389-83-9 ]
[ 1243164-72-8 ]

References: [1]Patent: WO2017/176812,2017,A1 .

16
[ 1036389-83-9 ]
C₈H₆BrN₃O₂ [ No CAS ]

References: [1]Patent: WO2017/176812,2017,A1 .

17
[ 1036389-83-9 ]
2-(6-(4-cyclopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-5-fluoro-6-(pyridin-3-yl)isoindolin-1-one [ No CAS ]